Immune Response reports positive preliminary data from phase 2 study of IR103 in HIV

By Lisa Kerner

Charlotte, N.C., June 26 - The Immune Response Corp. said preliminary results of a phase 2 study of its second-generation HIV immunotherapy, IR103, demonstrated a positive safety profile and enhanced immunomodulatory effects over its first-generation product, Remune.

IR103, a formulation of Remune and a novel synthetic Toll-like receptor (TLR-9) agonist adjuvant, Amplivax, is designed to replenish immune cells that have been destroyed by the virus.

"The early results for IR103 in this clinical study are encouraging," lead investigator Andrea Gori said in a company news release.

"We can now proceed to further investigate the potential advance that IR103 may provide through its unique ability to actively stimulate an HIV patient's immune system to fight the virus."

The study results were presented at the International Symposium on HIV & Emerging Infectious Diseases in France.

Based in Carlsbad, Calif., Immune Response is an immuno-pharmaceutical company developing products to treat autoimmune and infectious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.